EXTON, Pa., June 23, 2020 /PRNewswire/ --Spherix recently published the inaugural report of the semiannual report series included in their RealTime Dynamix: Psoriatic Arthritis (EU)service, which captured the responses of 246 EU5 rheumatologists surveyed last month. The market intelligence firm has been closely tracking the US psoriatic arthritis (PsA) market on a quarterly basis since 2016 and has observed a relatively stagnant treatment landscape over the past few years. However, the possible introduction of Janssen's IL-23 inhibitor, Tremfya, to both the EU and US PsA markets before the year is over will carry with it the debut of a novel class to the indication, likely causing a stir in rheumatologists' treatment algorithm.
According to the new Spherix report, TNF inhibitor use for the treatment of PsA across the EU5 remains widespread, accounting for two-thirds of all biologic/small molecule-treated patients. For adalimumab, etanercept and infliximab, use is relatively split between biosimilars and the branded reference agent (AbbVie's Humira, Amgen's Enbrel, and Janssen's Remicade, respectively), though use of Enbrel has been most eroded by generic competition.
When looking at use of alternate mechanism of action (AMOA) agents, Novartis' Cosentyx is the most penetrated brand across the EU5, showcasing the highest user base and self-reported brand share among all AMOA agents, followed by Janssen's Stelara. Eli Lilly's second-in-class IL-17 inhibitor, Taltz, has yet to reach the same heights as Cosentyx, and EU5 rheumatologists most often cite their level of experience as the key differentiator between the two agents. This, coupled with the fact that only one-quarter of respondents believe the two IL-17 inhibitors to be completely interchangeable, suggests that Taltz has ample room to grow (given more experience with the brand).
In fact, when assessing rheumatologists' six-month projected biologic/small molecule brand share in PsA, Taltz and Pfizer's Xeljanz are poised for the greatest growth. While Xeljanz is currently even-keeled with Taltz, Lilly's agent is expected to outgrow Pfizer's in the coming months, with anticipated share of Taltz expected to nearly double.
Despite the advantage of oral administration and a unique MOA in the EU PsA market, Xeljanz is struggling to surpass rheumatologists' expectations, and the majority of use is seen in second or later lines of therapy. Just shy of two years post EMA approval, respondents report long-term safety concerns as the most common primary barrier to use for the JAK inhibitor.
Interestingly, Spherix data included in a complementary service reveals EU5 rheumatologists' noticeable preference for Lilly's Olumiant over Xeljanz for the treatment of rheumatoid arthritis, and respondents perceive Olumiant's JAK 1/2 pathway to be the safest option regarding cardiovascular side effects. This is likely a contributing factor in addition to a longer tenure and multiple EMA-approved dosing options in RA to the slower anticipated uptake of Xeljanz in the EU5 PsA market, as prescribers may see the TNF or IL-17 inhibitors as more viable options concerning both safety and efficacy.
Nonetheless, Tremfya (guselkumab), which is in Phase 3 clinical trials for treatment in PsA, is currently under EMA review for EU approval. The introduction of the IL-23 inhibitor will be the first of its class and is expected to throw a curve in rheumatologists' current trajectories. Surveyed rheumatologists also provided six-month projected use patterns considering the commercialization of Tremfya in PsA, and respondents estimate the new entrant will capture a sizeable portion of the market.
As a result, in a post-Tremfya world, EU5 rheumatologists predict continued erosion of the TNF inhibitors and a significant reduction in the projected growth for Taltz and Xeljanz. Cosentyx share is also slated to decrease while Stelara and BMS' Orencia remain relatively stable. One-quarter of surveyed respondents consider Tremfya to be an advance over other treatments, and the majority cite "efficacy in skin/use in psoriasis" as the greatest advantage of the IL-23 class. On the other hand, perceived efficacy of the IL-23 inhibitors could also contribute to lackluster penetration of the class, as overall efficacy was also the number one disadvantage reported by rheumatologists, likely referring to unknown performance in joints for the treatment of PsA.
That is where other late-stage pipeline assets come in and set the stage for an even more dynamic future treatment landscape. Earlier this month, AbbVie announced the EMA regulatory application submission for their JAK inhibitor, Rinvoq (upadacitinib), for the treatment of PsA. While the JAK will likely come second to the Tremfya launch and will not bring with it the introduction of a novel class, early uptake and encouraging efficacy perceptions of Rinvoq for the treatment RA will likely translate to greater use in PsA (granted looming safety concerns surrounding the class do not prevail).
About RealTime DynamixRealTime Dynamix: Psoriatic Arthritis (EU)is an independent service providing strategic guidance through rapid and comprehensive semiannual reports, which include market trending, launch tracking, and a fresh infusion of unique content with each wave.
About Spherix Global InsightsSpherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:Kristen Henn, Business Development ManagerEmail:info@spherixglobalinsights.comwww.spherixglobalinsights.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/eu5-rheumatologists-expect-the-introduction-of-janssens-tremfya-in-psoriatic-arthritis-to-blunt-anticipated-growth-of-eli-lillys-taltz-novartis-cosentyx-and-pfizers-xeljanz-301081366.html
SOURCE Spherix Global Insights
View original post here:
EU5 Rheumatologists Expect the Introduction of Janssen's Tremfya in Psoriatic Arthritis to Blunt Anticipated Growth of Eli Lilly's Taltz, Novartis'...
- Annual Health Observances | NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - October 6th, 2024
- Obesity dampens rheumatoid arthritis treatment effectiveness, satisfaction - Healio - October 6th, 2024
- Patient Perspectives: Finding Grace While Living With Rheumatoid Arthritis - Rheumatology Advisor - October 6th, 2024
- Rheumatoid arthritis tied to heavy economic and human burdens - Medical Xpress - October 6th, 2024
- Dual therapy can have synergistic effect in difficult-to-treat inflammatory diseases - Healio - October 6th, 2024
- Hand-Held Scanner Could Transform Cancer and Arthritis Diagnosis - Technology Networks - October 6th, 2024
- Medical imaging breakthrough could transform cancer and arthritis diagnosis - University College London - October 6th, 2024
- Citryll and leading rheumatology centres receive - GlobeNewswire - October 6th, 2024
- Its going to be ubiquitous: Weight loss drugs may aid rheumatic disease treatment - Healio - October 6th, 2024
- Comorbidities Associated With Psoriasis: 5 Things to Know - Medscape - October 6th, 2024
- Opinion: Let's treat arthritis with the seriousness it deserves - Vancouver Sun - October 6th, 2024
- New handheld scanner technology could transform cancer and arthritis diagnosis - The Engineer - October 6th, 2024
- Stem cell therapy for osteoarthritis: Functional cartilage regeneration using 3d bioprinting technology - Open Access Government - October 6th, 2024
- Handheld scanner could transform cancer and arthritis diagnosis study - The Independent - October 6th, 2024
- Ankylosing Spondylitis and Self-Care: 6 Science-Backed Tips - Everyday Health - October 6th, 2024
- From a Labrador with arthritis to a goldfishs lifespan your pet queries answered... - The Sun - October 6th, 2024
- 15 Home Essentials That Make Life Easier If You Have Arthritis - HuffPost - September 21st, 2024
- Gout, a painful form of arthritis, is on the rise. Avoiding red meat and alcohol can help. - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pain - MedicineNet - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - U.S. News & World Report - September 21st, 2024
- Arthritis can flare up in colder weather: Tips to easing the pan - Medical Xpress - September 21st, 2024
- See how Waymo is bringing Arthritis Foundation of Arizona families to the ballpark - ABC15 Arizona in Phoenix - September 21st, 2024
- Prevalence of Loneliness in Inflammatory Arthritis and its Association with Disease Activity - Physician's Weekly - September 21st, 2024
- Psoriatic Arthritis and Gluten: Whats the Link? - Health Central - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Southernminn.com - September 21st, 2024
- 6 Knee Injuries That Can Cause Arthritis - Health News Hub - September 21st, 2024
- The Best Rheumatoid Arthritis Self-Care Tips To Soothe Painful Joints and Improve Mobility - Yahoo Life - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - El Paso Inc. - September 21st, 2024
- Shifting kneecap in kids? Early ligament repair can prevent arthritis in young Age: Experts - The Times of India - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Shelbynews - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Citizentribune - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - News-Daily.com - September 21st, 2024
- Casavant: Access to virtual care at risk for millions of arthritis patients - Daily Independent - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - Avery Journal Times - September 21st, 2024
- Arthritis Can Flare Up in Colder Weather: Tips to Easing the Pan - The Elkhart Truth - September 21st, 2024
- What To Eat (And Skip) on a Rheumatoid Arthritis Diet To Reduce Painful Inflammation - Woman's World - September 21st, 2024
- Tiny knee bone linked to arthritis may have helped humans walk upright, scientists suggest - Sky News - September 13th, 2024
- Medical Marijuana Helps People With Arthritis And Other Rheumatic Conditions Reduce Use Of Opioids And Other Medications, Study Shows - Marijuana... - September 13th, 2024
- My 'stomach bug' turned out to be an agonising pain condition that left me wheelchair bound within four years - Daily Mail - September 13th, 2024
- Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis - Nature.com - September 13th, 2024
- Early Use of Steroids Linked to Prolonged Treatment in RA - Medscape - September 13th, 2024
- How rheumatoid arthritis and Down syndrome are helping researchers find treatments for Alzheimer's - Colorado Public Radio - September 13th, 2024
- Is It Bad to Drink Coffee if You Have Rheumatoid Arthritis? - Health Central - September 13th, 2024
- Harnessing Patient Insights: The Role of PROs in Managing Psoriasis and Psoriatic Arthritis - MD Magazine - September 13th, 2024
- Spotlight On Maryland-The Arthritis Foundation - Audacy - September 13th, 2024
- Gum disease and arthritis: How bacteria in your mouth could be hurting your joints - Hindustan Times - September 13th, 2024
- An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis - Nature.com - September 13th, 2024
- Sky's Angel Reese to have wrist surgery Tuesday, be in cast for six weeks - USA TODAY - September 13th, 2024
- A message from AdventHealth: Swing into action to fight Arthritis - Johnson County Post - September 13th, 2024
- Bio-Thera Solutions and Biogen Publish Phase 3 Clinical Trial Data for TOFIDENCE (BAT1806/BIIB800), an approved Biosimilar referencing tocilizumab in... - September 13th, 2024
- Failed Remission in Early RA No Better With Added Etanercept - Medscape - August 25th, 2024
- Trapeziectomy and Mini TightRope Suspensionplasty for First Carpometacarpal Joint Arthritis - Cureus - August 25th, 2024
- What is early arthritis? UAB experts weigh in - University of Alabama at Birmingham - August 25th, 2024
- Evaluating and Adjusting Rheumatoid Arthritis Treatment: Adhering to ACR Guidelines for csDMARDs and Advanced Therapies - MD Magazine - August 25th, 2024
- Gelsolin alleviates rheumatoid arthritis by negatively regulating NLRP3 inflammasome activation - Nature.com - August 25th, 2024
- The association between the aggregate index of systemic inflammation and risk of rheumatoid arthritis: retrospective analysis of NHANES 19992018 -... - August 25th, 2024
- High Prevalence of Tendon Issues in Hand Osteoarthritis - Medscape - August 25th, 2024
- The point of knee shots - Harvard Health - August 25th, 2024
- Exploring the Discrepancy Between Patient Perception and Disease Activity Assessments - MD Magazine - August 25th, 2024
- Do you have knee pain from osteoarthritis? You might not need surgery. Here's what to try instead - ABC News - August 25th, 2024
- Blood test provides early alert to knee arthritis - Cleveland Jewish News - August 7th, 2024
- Lifestyle tips for youth's bone health: Avoid these habits to prevent arthritis - Hindustan Times - January 25th, 2024
- Arthritis | Johns Hopkins Medicine - January 9th, 2024
- What Is Arthritis? | Arthritis Foundation - May 17th, 2023
- Procedure to Surgery for Arthritis Is Recommended After First Failed Non-Operative Therapy - DocWire News - March 29th, 2023
- Higher Prevalence of Sarcopenia Reported in Patients with Rheumatoid Arthritis - Rheumatology Network - October 7th, 2022
- Exploring the Relationship Between Psoriatic Arthritis and Psoriasis - Dermatology Times - October 7th, 2022
- Are Tomatoes Bad For Arthritis? Here's What An MD Has To Say - Women's Health - October 7th, 2022
- Tocilizumab for Treating ICI-Induced Arthritis and Colitis - DocWire News - October 7th, 2022
- Why Arthritis Is A Clear And Present Danger, And How We Can Fight It - CNBCTV18 - October 7th, 2022
- Arthritis: Five cruciferous veg 'block inflammatory process' - backed by 10-year study - Express - October 7th, 2022
- 5 Exercise Habits for Arthritis in Your 50s - Eat This, Not That - October 7th, 2022
- Arthritis: 8 types of fish can cause acid crystals to build up in joints - 'very painful' - Express - October 7th, 2022
- EMA Issues Positive Opinion on the Safety of Filgotinib - Medscape - October 7th, 2022
- Lamb of God's Willie Adler on their new album Omens - Guitar.com - October 7th, 2022
- Eat Your Way to Stronger Bones & Healthy Joints - Daniel Island News - October 7th, 2022
- Long COVID could be linked to a totally different (and common) virus, new study finds - Fortune - October 7th, 2022
- My body hurt so much I thought I had arthritis & I started forgetting people it was the menopause, says K... - The Sun - October 7th, 2022
- 'Terrified' nan cant afford heating despite painful arthritis and will do 'Christmas shopping at Poundland' - Lincolnshire Live - October 7th, 2022
- Dirt & Glory's Alex Moss Cherishes the 'Real World Impact' of His Role | LBBOnline - Little Black Book - LBBonline - October 7th, 2022